Search
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]
Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB10998ApprovedInvestigationalWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...
Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 Kit, Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11044ApprovedWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...
Mixtures: Medical Provider Single Use EZ Flu Shot Afluria 2016-2017, Medical Provider Single Use EZ Flu Shot Fluvirin 2016-2017SVV-001
go.drugbank.com/drugs/DB06129InvestigationalSVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in
Protein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalProtein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthe...
Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETProducts: CEPROTIN 500 IU IV ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ İÇEREN FLAKONAP5280
go.drugbank.com/drugs/DB05112ExperimentalAP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approvedpatients with congenital athymia: this marks the first and only FDA-approved treatment for such therapeutic indication. … [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric
Exagamglogene autotemcel
go.drugbank.com/drugs/DB15572ApprovedInvestigationalIt was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive crises. … [L49246] In January 2024, exagamglogene autotemcel received an additional FDA approval for the treatment of transfusion-dependent β-thalassemia.
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigational[L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic … [A236359] Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...